For patients transitioning from rituximab to ravulizumab, meningococcal vaccination can be safely done within 6 months after stopping rituximab.

Children with pediatric-onset multiple sclerosis (POMS) have shorter telomeres, suggesting MS may accelerate biological aging.

The US Food and Drug Administration has approved a new drug application for a tablet version of Evrysdi (risdiplam) for people living with spinal muscular atrophy (SMA).

Cladribine treatment for relapsing multiple sclerosis improves health-related quality of life and preserves cognitive function after 4 years.

Mild cognitive impairment and Alzheimer disease have a low prevalence among newly diagnosed patients with multiple sclerosis.

Compared with placebo, zavegepant nasal spray yielded sustained relief of acute pain and function in migraine.

Sexual dysfunction and depression are common and associated with increased disability in patients with multiple sclerosis.

Contemporary estrogen-progestin contraceptives are associated with an increased risk for ischemic stroke and myocardial infarction.

Efficacy of treatment is maintained during the switch from IV anti-CD20 therapies to ofatumumab in relapsing MS regardless of race/ethnicity.

There is an inverse bidirectional association between cancer and dementia, a relationship that holds across cancer and dementia subtypes.

Women with epilepsy may have offspring with decreased bone metabolism and lower birth weight, according to a study.

Among stroke survivors, the risk of developing dementia after stroke is significantly high, highlighting the need for targeted prevention strategies.